Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality

Blood

Volumn 125, Issue 9, 2015, Pages 1470-1476

  Goel, Ruchika ^a,b   Ness, Paul M ^a   Takemoto, Clifford M ^b   Krishnamurti, Lakshmanan ^c   King, Karen E ^a   Tobian, Aaron A R ^a  

^a Department of Neurology   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; ADULT; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITALIZATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE DISORDER; THROMBOCYTE TRANSFUSION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VEIN THROMBOSIS; ADOLESCENT; ADVERSE EFFECTS; AGED; BLOOD PLATELET DISORDERS; CHILD; COMPLICATION; FOLLOW UP; INFANT; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PRESCHOOL CHILD; PROGNOSIS; PURPURA, THROMBOCYTOPENIC; STATISTICS AND NUMERICAL DATA; STROKE; SURVIVAL RATE; THROMBOSIS; TRENDS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELET DISORDERS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; INFANT; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET TRANSFUSION; PROGNOSIS; PURPURA, THROMBOCYTOPENIC; STROKE; SURVIVAL RATE; THROMBOSIS; YOUNG ADULT;

EID: 84923859033     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-10-605493     Document Type: Article

References (51)

1. Nieswandt B, Pleines I, Bender M. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke. J Thromb Haemost. 2011;9(suppl 1):92-104.
2. Montalescot G. Platelet biology and implications for antiplatelet therapy in atherothrombotic disease. Clin Appl Thromb Hemost. 2011;17(4):371-380.
3. Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J. 2010;74(4):597-607.
4. Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost. 2009;102(2):248-257.
5. Boudreau LH, Duchez AC, Cloutier N, et al. Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation. Blood. 2014;124(14):2173-2183.
6. Harkness DR, Byrnes JJ, Lian EC, Williams WD, Hensley GT. Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. JAMA. 1981;246(17):1931-1933.
7. Gottschall JL, Pisciotta AV, Darin J, Hussey CV, Aster RH. Thrombotic thrombocytopenic purpura: experience with whole blood exchange transfusion. Semin Thromb Hemost. 1981;7(1):25-32.
8. Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature. Medicine (Baltimore). 1981;60(6):413-428.
9. Babcock RB, Dumper CW, Scharfman WB. Heparin-induced immune thrombocytopenia. N Engl J Med. 1976;295(5):237-241.
10. Cimo PL, Moake JL, Weinger RS, Ben-Menachem YB, Khalil KG. Heparin-induced thrombocytopenia: association with a platelet aggregating factor and arterial thromboses. Am J Hematol. 1979;6(2):125-133.
11. Weismann RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. AMA Arch Surg. 1958;76(2):219-225.
12. Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med. 2003;127(7):834-839.
13. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654-666.
14. Warkentin TE. HIT: more than just heparin. Blood. 2010;115(9):1664-1665.
15. Warkentin TE. HIT paradigms and paradoxes. J Thromb Haemost. 2011;9(suppl 1):105-117.
16. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003;121(4):535-555.
17. Buchanan GR, Scher CS, Button LN, Nathan DG. Use of homologous platelet survival in differential diagnoses of chronic thrombocytopenia in childhood. Pediatrics. 1977;59(1):45-54.
18. Stoll D, Cines DB, Aster RH, Murphy S. Platelet kinetics in patients with idiopathic thrombocytopenic purpura and moderate thrombocytopenia. Blood. 1985;65(3):584-588.
19. Carr JM, Kruskall MS, Kaye JA, Robinson SH. Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med. 1986;80(6):1051-1054.
20. Salama A, Kiesewetter H, Kalus U, Movassaghi K, Meyer O. Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia. Thromb Haemost. 2008;100(5):762-765.
21. Spahr JE, Rodgers GM. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. Am J Hematol. 2008;83(2):122-125.
22. Danese MD, Lindquist K, Gleeson M, Deuson R, Mikhael J. Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura. Am J Hematol. 2009;84(10):631-635.
23. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-4207.
24. Kumar A, Mhaskar R, Grossman BJ, et al AABB Platelet Transfusion Guidelines Panel. Platelet transfusion: a systematic review of the clinical evidence. [published online ahead of print November 12, 2014]. Transfusion.
25. American Hospitals Association. Fast facts on US hospitals. Available at: www.aha.org/research/rc/stat-studies/fast-facts.shtml. Accessed December 2014.
26. HCUP Data Use Agreement Training. Available at: www.hcup-us.ahrq.gov/team/NationwideDUA.jsp. Accessed December 2014.
27. Localio AR, Berlin JA, Ten Have TR, Kimmel SE. Adjustments for center in multicenter studies: an overview. Ann Intern Med. 2001;135(2):112-123.
28. Hicks CW, Hashmi ZG, Velopulos C, et al. Association between race and age in survival after trauma. JAMA Surg. 2014;149(7):642-647.
29. Software MAD. 3M™ APR DRG software. Available at: http://solutions.3m.com/wps/portal/3M/en-US/Health-Information-Systems/HIS/Products-and-Services/Products-List-A-Z/APR-DRG-Software/.
30. Allford SL, Hunt BJ, Rose P, Machin SJ; Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol. 2003;120(4):556-573.
31. Rock G, Kelton JG, Shumak KH, Buskard NA, Sutton DM, Benny WB; Canadian Apheresis Group. Laboratory abnormalities in thrombotic thrombocytopenic purpura. Br J Haematol. 1998;103(4):1031-1036.
32. Duffy SM, Coyle TE. Platelet transfusions and bleeding complications associated with plasma exchange catheter placement in patients with presumed thrombotic thrombocytopenic purpura. J Clin Apher. 2013;28(5):356-358.
33. Swisher KK, Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B, George JN. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion. 2009;49(5):873-887.
34. th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(suppl 2): e495S-e530S.
35. Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost. 2005;94(1):132-135.
36. Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest. 2006;129(6):1407-1416.
37. Hopkins CK, Goldfinger D. Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. Transfusion. 2008;48(10):2128-2132.
38. Refaai MA, Chuang C, Menegus M, Blumberg N, Francis CW. Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. J Thromb Haemost. 2010;8(6):1419-1421.
39. Tun NM, Bo ZM, Ahluwalia M, Guevara E, Villani GM. A rare case of intracerebral hemorrhage complicating heparin-induced thrombocytopenia with thrombosis: a clinical dilemma ameliorated by novel use of plasmapheresis. Int J Hematol. 2012;96(4):513-515.
40. Cuker A, Cines DB. How I treat heparin-induced thrombocytopenia. Blood. 2012;119(10):2209-2218.
41. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-186.
42. Blanchette VS, Carcao M. Childhood acute immune thrombocytopenic purpura: 20 years later. Semin Thromb Hemost. 2003;29(6):605-617.
43. De Mattia D, Del Vecchio GC, Russo G, et al AIEOP-ITP Study Group. Management of chronic childhood immune thrombocytopenic purpura: AIEOP consensus guidelines. Acta Haematol. 2010;123(2):96-109.
44. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.
45. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(4):574-596.
46. Kawano N, Hasuike S, Iwakiri H, et al. Portal vein thrombosis during eltrombopag treatment for immune thrombocytopenic purpura in a patient with liver cirrhosis due to hepatitis C viral infection. J Clin Exp Hematop. 2013;53(2):151-155.
47. Heckbert SR, Kooperberg C, Safford MM, et al. Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. Am J Epidemiol. 2004;160(12):1152-1158.
48. Health Cost and Utilization Project Quality Control Procedures. Available at: www.ahrq.gov/data/hcup/sasddocu/techsupp2.pdf. Accessed December 2014.
49. Comparative Analysis of HCUP and NHDS Inpatient Discharge Data. Available at: www.ahrq.gov/data/hcup/nhds/niscomp.htm.
50. George JN, Vesely SK, Terrell DR, et al. The Oklahoma Thrombotic Thrombocytopenic Purpura-haemolytic Uraemic Syndrome Registry. A model for clinical research, education and patient care. Hamostaseologie. 2013;33(2):105-112.
51. Wahl PM, Bohn RL, Terrell DR, George JN, Ewenstein B. Health care utilization of patients diagnosed with idiopathic thrombotic thrombocytopenic purpura in a commercially insured population in the United States. Transfusion. 2012;52(7 Pt 2):1614-1621.